Teva VP Ika Abravanel resigns
Enlivex Therapeutics is developing Apocell for treating graft-versus-host disease in bone marrow transplants.
Hadasit Bio Holdings Ltd. (TASE:HDST; Bulletin Board: HADSY) portfolio company Enlivex Therapeutics Ltd. has obtained orphan drug status from the US Food and Drug Administration (FDA) for its Apocell treatment for graft-versus-host disease (GVHD). GVHD affects 70% of patients who receive bone marrow transplants from an unrelated donor, and can be lethal.
"The main achievement of orphan drug status is the seven years exclusivity, guaranteeing no competition irrespective of patents, and significant regulatory easements, which we believe will shorten marketing approval of the drug in the US, reducing costs," said Enlivex CEO Alon Moran.
"The results of clinical trials of Apocell showed strong efficacy and safety indications of the treatment, which allows transplants from unrelated donors while minimizing severe GVHD complications. We intend to pursue development of the drug from a Phase IIb clinical trial through full marketing approval in the US."
GVHD affects 30,000 people annually in the US and Europe. It is basically an autoimmune disease, in which the body's immune system attacks the implant as a foreign body. There is no effective treatment for the disease. Current treatments involve suppressing the body's immune system, but this exposes patients to disease.
Apocell induces tolerance in the patient's immune system by activating the natural cell death mechanism, apoptosis, immediately after a bone marrow transplant.
"FDA orphan drug status for Enlivex's Apocell is important regulatory recognition of the drug's necessity," said Hadasit Bio CEO Ophir Shahaf.
Hadasit Bio, a unit of Hadasit - the Technology Transfer Company of Hadassah Medical Organization , owns 92% of Enlivex. Hadasit Bio's share price rose 23.5% by early afternoon on the TASE to NIS 0.358, giving a market cap of NIS 45 million. The share closed at $1.60 on the Bulletin Board yesterday.
Published by Globes [online], Israel business news - www.globes-online.com - on April 3, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
You comment was recieved and soon will be published.
Load more comments
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.